Paired WES and low coverage WGS of osteosarcoma

Longitudinal genome-sequencing analysis of 12 patients with metastatic or refractoryosteosarcoma. The study was approved at the University Hospital Basel, following the approval ofthe ethical committee for mutational analysis of anonymized samples(“Ethikkommission beider Basel” ref. 274/12). Informed consent was obtained fromall 12 patients. All tumor samples were evaluated by an experienced bonepathologist to confirm the diagnosis.WES and low coverage WGS are aligned against the reference genome GRCh37. More details in the associated publication.

对12名患有转移性或难治性骨肉瘤的患者进行纵向基因组测序分析。本研究已获得巴塞尔大学医院的批准，并遵循了匿名样本突变分析伦理委员会（“Ethikkommission beider Basel” ref. 274/12）的批准。从所有12名患者处获得了知情同意。所有肿瘤样本均由经验丰富的骨病理学家进行评估，以确认诊断。全外显子测序（WES）和低覆盖度全基因组测序（WGS）与参考基因组GRCh37进行比对。更多详情请参见相关出版物。